Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Future Of Targeted Therapy: Combining Novel Agents

L. Gianni
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The anti-HER2 monoclonal antibody Herceptin® demonstrates significant clinical benefits in patients with HER2-positive metastatic breast cancer (MBC). However, the combination of Herceptin plus anthracyclines, although efficacious, demonstrated a higher than expected incidence of cardiotoxicity. Therefore, studies are currently investigating Herceptin in combination with alternative anthracyclines, such as epirubicin and liposomal doxorubicin. Investigators are also beginning to examine the potential of Herceptin plus hormonal therapy, a combination that will delay the need to use cytotoxic chemotherapy. Furthermore, a plethora of novel agents have been developed that target the processes of tumorigenesis, including HER1 tyrosine-kinase inhibitors, farnesyl-transferase inhibitors, and cyclooxygenase 2 (COX2) inhibitors. Preclinical data demonstrate that the combination of Herceptin with these agents can produce at least additive effects and therefore a rationale exists to investigate these regimens in the clinical setting. As a result of the targeted nature of these agents, it is anticipated that such strategies will have favorable safety profiles. It is possible that through the development and use of biological anticancer agents, such as Herceptin, future anticancer regimens may be specifically tailored to each patient based on their molecular characteristics.
This paper references
Chemotherapy of metatstatic breast cancer: What to expect in 2001 and beyond. The Oncologist 2001;6:133–146
FJ Esteva (2001)
The ErbB signalling
I Alroy (2001)
10.1016/S0014-5793(97)00412-2
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions
I. Alroy (1997)
10.1038/sj.onc.1202307
Regulation of Cyclooxygenase-2 pathway by HER2 receptor
R. Vadlamudi (1999)
10.1016/S0959-8049(97)10157-5
ERBB2 oncogene in human breast cancer and its clinical significance.
F. Révillion (1998)
10.1016/1040-8428(94)00144-I
Epidermal growth factor-related peptides and their receptors in human malignancies.
D. Salomon (1995)
10.1159/000066200
What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?
R. Bell (2002)
10.1023/A:1005798224288
Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
L. Witters (2004)
Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: Preliminary results of a prospective study (abstract 223)
E Alba (2001)
Breast Cancer Res Treat 1993;27:83–93
H Kunisue (1993)
10.1016/S0093-7754(01)90197-6
Liposomal anthracyclines for breast cancer.
J. Sparano (2001)
10.1016/S0065-230X(08)60784-8
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.
L. Klapper (2000)
10.1126/SCIENCE.2885917
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. D. Di Fiore (1987)
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
J. Masferrer (2000)
10.1200/JCO.20.6.1467
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
A. Lipton (2002)
Herceptin ® in combination with epirubicin plus cyclophosphamide : Cardiac safety and efficacy in patients with metastatic breast cancer ( abstract 236 )
H Eidtmann (2002)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1038/sj.onc.1202526
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M. Pegram (1999)
10.3892/OR.7.6.1377
Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model.
G. Alshafie (2000)
Humanization of an anti-p 185 HER 2 antibody for human cancer therapy ( antibody engineering / site-directed mutagenesis / c-erbB2 / neu )
P. Carter
10.2165/00003495-199345050-00011
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
G. Plosker (1993)
10.1200/JCO.1999.17.9.2639
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
Character - isation of cyclooxygenase - 2 ( COX - 2 ) expression and HER 2 / neu in human breast , colon , and prostate cancer ( abstract 101 )
AT Koki (2000)
A safe, outpatient regimen of Herceptin and IL-2 in HER-2 positive metastatic breast cancer therapy (abstract 2008)
TL Repka (2001)
10.1054/bjoc.1999.0875
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
H. Kunisue (2000)
Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
A. Lee (2001)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1073/PNAS.89.10.4658
Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor.
D. Ignar-Trowbridge (1992)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1016/S0959-8049(01)81118-7
Herceptin and interleukin-12 combination therapy in patients with HER2/neu-overexpressing malignancies: a phase I trial
R. Parihar (2001)
10.1023/A:1008313310474
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.
O. Stål (2000)
10.1016/0022-4731(89)90072-1
Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
A. Harris (1989)
10.1517/13543784.8.10.1623
Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.
Koki (1999)
10.1111/j.1349-7006.2000.tb01030.x
Chemoprevention by Nimesulide, a Selective Cyclooxygenase‐2 Inhibitor, of 2‐Amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine (PhIP)‐induced Mammary Gland Carcinogenesis in Rats
Seiichi Nakatsugi (2000)
10.1159/000066198
HER-Targeted Tyrosine-Kinase Inhibitors
J. Baselga (2002)
10.1002/j.1460-2075.1996.tb00356.x
ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
D. Karunagaran (1996)
10.1016/S0002-9610(05)80897-9
Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.
A. Osaki (1992)
10.1016/S0959-8049(01)81216-8
Cardiac safety of herceptin(R) in combination with epirubicin plus cyclophosphamide: interim results of a phase II study in patients with metastatic breast cancer
M. Untch (2001)
10.1159/000055403
Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer
N. Cook-Bruns (2001)
Cardiac safety and antitumour activity of doxorubicin and taxol ® ( AT & T ) when Herceptin ® is initiated with AT or T alone in women with HER 2 - positive advanced breast cancer ( abstract 698 )
L Gianni (2001)
A Phase I , pharmacokinetic , and biological correlative study of R 115777 and trastuzumab ( Herceptin ) in patients with advanced cancer ( abstract 322 )
G Schwartz (2001)
10.7326/0003-4819-125-1-199607010-00008
Anthracycline-Induced Cardiotoxicity
K. Shan (1996)
Coexpression of erbB 2 and erbB 3 proteins reconstitutes a high affinity receptor for heregu
MX Sliwkowski (1994)
creased expression of the putative growth factor receptor p 185 HER 2 causes transformation and tumorigenesis of HIH 3 T 3 cells
RM Hudziak (1987)
HER 2 overexpression predicts adjuvant tamoxifen ( TAM ) failure for early breast cancer ( EBC ) : Complete data at 20 yr of the Naples GUN randomized trial ( abstract 289 )
AR Bianco (2000)
10.1097/00001813-200112004-00002
Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies
I. Smith (2001)
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
R. Harris (2000)
10.1016/S1040-8428(00)00107-4
Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.
M. Ranson (2001)
10.1200/JCO.2001.19.18.3808
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
M. Ellis (2001)
10.1016/0092-8674(87)90592-7
Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
P. P. D. Fiore (1987)
10.1016/S0959-8049(01)81197-7
Effect of cardiac dysfunction on treatment outcome in the herceptin pivotal trial
D. Tripathy (2001)
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.
L. Read (1990)
10.11501/3168488
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
國末 浩範 (2000)
10.1038/74704
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
R. Clynes (2000)
10.1634/THEONCOLOGIST.6-2-133
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
F. Esteva (2001)
P 185 HER 2 signal transduction in breast cancer cells
GK Scott (1991)
10.1007/BF00683195
The role of erbB2 signal transduction pathways in human breast cancer
R. Lupu (2004)
10.1016/s0021-9258(18)98683-7
p185HER2 signal transduction in breast cancer cells.
G. Scott (1991)
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
M. Sliwkowski (1994)
peutic agents used for treatment of human breast cancers
R Bell (2002)
Inhibitory effects of combinations of HER2/neu antibody and chemothera
M Pegram (1999)
Therapeutic advantage of chemotherapy drugs in combination with Herceptin ® against human breast cancer cells with HER - 2 / neu overexpression ( abstract 467 )
G Konecny (1999)
10.1093/OXFORDJOURNALS.ANNONC.A058514
Drugs ten years later: epirubicin.
G. Bonadonna (1993)
10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J
Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells
W. Carson (2001)
10.2165/00002512-199915050-00006
Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
D. Ormrod (1999)
10.1159/000066203
Perspectives on Anti-HER Monoclonal Antibodies
M. Ranson (2002)
10.1677/ERC.0.0080097
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
L. Howe (2001)
tibody. Breast Cancer Res Treat 1997;42:1–5
DS Salomon (1997)
10.1016/S0304-3835(98)00254-7
Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention.
G. Winde (1998)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
10.1053/GAST.2001.24844
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
M. Mann (2001)
10.1093/ANNONC/MDF020
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
N. Normanno (2002)
TLC D 99 ( D , Myocet ) and Herceptin ( H ) is safe in advanced breast cancer ( ABC ) : Final cardiac safety and efficacy analysis ( abstract 216 )
M Theodoulou (2002)
10.1634/THEONCOLOGIST.3-4-237
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
J. Ross (1998)
10.1073/PNAS.89.10.4285
Humanization of an anti-p185HER2 antibody for human cancer therapy.
P. Carter (1992)
10.1073/PNAS.84.20.7159
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
R. Hudziak (1987)
10.1016/s0959-8049(02)80269-6
Farnesyl tranferase inhibitors and proteasome inhibitors
S. Johnston (2002)
10.1016/0304-419X(94)90012-4
The biology of erbB-2/neu/HER-2 and its role in cancer.
N. E. Hynes (1994)
10.7326/0003-4819-126-10-199705150-00020
Anthracycline-induced cardiotoxicity.
K. Shan (1996)
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
J. Baselga (1998)
10.1038/35052073
Untangling the ErbB signalling network
Y. Yarden (2001)
Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
M. Giai (1994)
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
R. Pietras (1995)
10.1093/emboj/16.7.1647
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
D. Graus-Porta (1997)



This paper is referenced by
10.1016/J.BREAST.2003.09.002
Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
T. Suter (2004)
10.1016/j.biopha.2009.09.018
Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Amit B. Shirode (2010)
Collateral resistance to oestrogen and erbB receptor activated growth in endocrine resistant breast cancer
Kate M. Moore (2007)
10.1158/1078-0432.CCR-1131-03
In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading
S. Abraham (2004)
10.4137/BCBCR.S2291
Effects of Celecoxib and Ly117018 Combination on Human Breast Cancer Cells in Vitro
K. Baumann (2009)
ISOPRENOID ANALOGS AS CHEMICAL GENETIC TOOLS TO PROVIDE INSIGHTS INTO FARNESYL TRANSFERASE TARGET SELECTION AND CELLULAR ACTIVITY
J. Troutman (2006)
10.1016/j.ejpb.2015.06.011
Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
J. Lee (2015)
10.1371/journal.pone.0117818
mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer
S. von der Heyde (2015)
10.1007/3-7643-7414-4_1
Dawn of a new era in molecular cancer therapeutics.
R. Schultz (2005)
Rarity of EGFR and c-ErbB-2 Overexpressions in Hepatocellular Carcinoma: An Immunohistochemical Study
W. Moon (2004)
Anthracycline and trastuzumab in breast cancer treatment.
M. Untch (2004)
10.1007/BF02968288
Sensitization of chemotherapy by anti-HER
A. Kataoka (2004)
eview erritin nanocages : A biological platform for drug delivery , imaging nd theranostics in cancer
arta Truffia (2016)
10.2165/00129785-200505050-00003
Pharmacodiagnostic Testing in Breast Cancer
J. Bartlett (2005)
10.1007/978-3-540-28266-2_46
Clinical Trials in the Era of Treatment Tailoring
P. Therasse (2006)
10.1038/sj.onc.1207392
Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection
T. Nakamura (2004)
10.1517/14656566.5.1.81
Trastuzumab-based combination therapy for breast cancer
F. Montemurro (2004)
10.2165/00063030-200418050-00001
Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals
E. Benedetti (2012)
10.1016/j.phrs.2016.03.002
Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer.
M. Truffi (2016)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
10.1016/J.CRITREVONC.2005.11.003
Clinical trials design and treatment tailoring: general principles applied to breast cancer research.
P. Therasse (2006)
Unravelling Drug Resistance Mechanisms in Breast Cancer
Silvia von der Heyde (2015)
10.1517/13543784.13.1.1
Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors
T. Sawyer (2004)
10.1007/s00384-011-1379-1
COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines
Songqiang Xie (2011)
Semantic Scholar Logo Some data provided by SemanticScholar